UK MHRA Authorises Inqlexzo for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer – Janssen-Cilag / Johnson & Johnson
According to the Medicines and Healthcare products Regulatory Agency (MHRA) website, an intravesical delivery system containing gemcitabine (Inqlexzo) has been authorised for the treatment of adults for certain… read more.
